Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 4Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Myeloid, Acute 52Myelodysplastic Syndromes 25Multiple Myeloma 25Precursor Cell Lymphoblastic Leukemia-Lymphoma 23Leukemia 23Lymphoma 22Lymphoma, Non-Hodgkin 21Leukemia, Lymphocytic, Chronic, B-Cell 21Melanoma 19Leukemia, Myelogenous, Chronic, BCR-ABL Positive 17Neoplasms 13Hodgkin Disease 13Neoplasm Metastasis 12Recurrence 11Hematologic Neoplasms 10Lymphoma, Large B-Cell, Diffuse 9Skin Neoplasms 8Neoplasms, Plasma Cell 8Myeloproliferative Disorders 8Lymphoma, Mantle-Cell 8Lymphoma, Follicular 8Lymphoma, B-Cell 8Kidney Neoplasms 8Ovarian Neoplasms 7Carcinoma, Non-Small-Cell Lung 7Burkitt Lymphoma 7Carcinoma, Renal Cell 6Triple Negative Breast Neoplasms 5Primary Myelofibrosis 5Anemia, Refractory, with Excess of Blasts 5

Interventions

Rituximab 4Etoposide 3Cyclophosphamide 3cobomarsen 2Vincristine 2Prednisone 2Ifosfamide 2Doxorubicin 2Carboplatin 2Brentuximab Vedotin 2ponatinib 1pomalidomide 1ibritumomab tiuxetan 1fludarabine 1dacetuzumab 1Vorinostat 1Melphalan 1Imatinib Mesylate 1Everolimus 1DTRMWXHS-12 1Cytarabine 1Carmustine 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Lymphatic Diseases × fludarabine × Clear all
NCT03743246 2024-08-15

A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)

Celgene

Phase 1/2 Terminated
21 enrolled 33 charts
LymphoidOther hematologic neoplasm

Immune System Diseases, Leukemia, Lymphatic Diseases, Lymphoma, Lymphoma, Non-Hodgkin, Lymphoproliferative Disorders, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡